Clinical Trial Update: Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a combination of vorinostat, cytarabine, and etoposide in patients with relapsed or refractory acute leukemia, myelodysplastic syndrome…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Etoposide (Etoposide)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia | Phase 1 | Status: COMPLETED